Dasatinib and Quercetin

Dasatinib and quercetin are two compounds that are being explored in combination for potential therapeutic benefits, particularly in the context of aging and health conditions associated with cellular aging.

1. Dasatinib:

• What it is: Dasatinib is a tyrosine kinase inhibitor primarily used to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It works by blocking specific enzymes that are involved in cancer cell growth.
• Potential in Aging: More recently, Dasatinib has been studied for its effects on senescent cells. Senescent cells are those that have stopped dividing but don’t die, and they accumulate with age, contributing to inflammation and tissue dysfunction. Studies suggest that Dasatinib may help clear senescent cells, potentially offering anti-aging benefits by reducing inflammation and promoting tissue regeneration.

2. Quercetin:

• What it is: Quercetin is a natural flavonoid found in various fruits, vegetables, and grains. It has antioxidant, anti-inflammatory, and anti-cancer properties. Quercetin is often used as a dietary supplement for its potential health benefits, such as reducing inflammation and improving cardiovascular health.
• Role in Senescence: Quercetin has been shown to help clear senescent cells as well. It is often paired with Dasatinib in research because of its ability to synergize with Dasatinib to promote the removal of senescent cells and reduce age-related inflammation.

3. Combination of Dasatinib and Quercetin:

• Synergistic Effect: When combined, Dasatinib and Quercetin may have a synergistic effect on senescent cell clearance. Research, especially from animal studies, indicates that this combination could help reduce age-related diseases like frailty, cardiovascular issues, and metabolic dysfunction.
• Mechanism: Dasatinib targets the pathways responsible for the survival of senescent cells, while quercetin promotes apoptosis (programmed cell death) of these cells. Together, they may enhance the clearance of senescent cells more effectively than either would alone, potentially improving tissue function and health span.

4. Clinical Research:

• Ongoing research is evaluating the safety and efficacy of this combination for age-related conditions, such as Alzheimer’s disease, cardiovascular diseases, and frailty. Early results in animal models have shown promising effects, but further human trials are needed to fully understand the long-term impacts and safety.

This combination shows promise, especially in the realm of aging and cellular health.

USE

Dasatinib and Quercetin, 100 mg Dasatinib and 1000 mg of Quercetin daily for 3 days then repeated every 2-4 weeks. This is the dose as recommended by Dr. Alan Green. Best taken on rest days.